top of page

Type 1 Diabetes Transplant Trial Offers Hope for Life Without Daily Insulin

19 hours ago
3 min read

An experimental treatment at the University of Chicago Medicine is offering encouraging results for people with type 1 diabetes: all 12 participants in an initial study group achieved insulin independence after receiving transplanted insulin-producing cells and a new anti-rejection drug. That means their bodies were making enough insulin for them to stop taking it through injections or a pump.


KTVQ-TV in Billings, Montana recently highlighted what that change has meant for Katie Beth Hand. After living with type 1 diabetes for 13 years, Hand received an islet cell transplant through the trial. At the time of her interview, she reported going 256 days without insulin. Her experience has drawn attention from diabetes advocates and families who have spent years hoping for treatments that could ease the daily demands of the disease.


In type 1 diabetes, the immune system attacks the pancreas’s insulin-producing beta cells. Islet transplantation replaces that lost function by introducing clusters of cells containing healthy beta cells. In this trial, the cells come from deceased organ donors and are delivered through a catheter into the liver, where they can begin producing insulin.


Islet transplantation has been studied for years. The focus of this research is a different way to protect the transplanted cells. The experimental drug tegoprubart blocks an immune signal involved in transplant rejection. Researchers are testing it in place of tacrolimus, a commonly used anti-rejection medicine that can damage the kidneys and the insulin-producing cells it is intended to protect.


Results presented in June 2026 went beyond reducing insulin use. According to Eledon Pharmaceuticals, which develops tegoprubart, all 12 participants had an A1C below 6.5%, with an average of approximately 5.4%. No severe low-blood-sugar episodes were reported after transplantation, despite participants having experienced recurrent severe episodes beforehand. Follow-up varied: the median was eight months, and the longest was 22 months.


Those findings are promising, but a small pilot study cannot establish how well a treatment will work across the broader diabetes population or how long its benefits will last. Participants were carefully selected adults with long-standing type 1 diabetes and serious problems with low blood sugar despite diabetes management. Larger studies and longer follow-up are needed to assess lasting benefits and risks.


Participants also continue taking medicines to suppress the immune system, including tegoprubart alongside other anti-rejection drugs. These medications help protect the transplant but can carry risks, including infections. Although early findings suggest the approach may avoid some harms associated with tacrolimus, it has not been shown to eliminate the risks of immune suppression or provide a permanent cure.


Access remains another challenge. Donor islet cells are in limited supply, and some recipients need more than one infusion. Researchers must address both the safety of protecting transplanted cells and the availability of enough cells to make this approach accessible to more people.


The research is moving forward. In a November 2026 update, Eledon reported that the University of Chicago study had enrolled three additional participants. The company also said the FDA had cleared its application to conduct a separate planned islet-transplant trial. That clearance allows research to proceed; it is not approval to market tegoprubart as a diabetes treatment.


For people living with type 1 diabetes, the possibility of producing their own insulin again is meaningful. The next stage of research will help determine whether the results seen in this small group can translate into a lasting, acceptably safe option for more patients.

 
 
 

Comments


bottom of page